Print

Novo Nordisk A/S (NVO): FDA Discloses Focus of Advisory Committee Meeting on Insulin Degludec and Insulin Degludec/Insulin Aspart  
10/26/2012 1:04:08 PM

BAGSVAERD, DENMARK--(Marketwire - October 25, 2012) -


Company announcement No 68 / 2012:

http://hugin.info/2013/R/1652555/533479.pdf

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.
    
Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1652555]


Further information:
Media:
Mike Rulis
Tel: (+45) 3079 3573
Email Contact

In North America:
Ambre Morley
Tel: (+1) 609 216 5240
Email Contact

Investors:
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4303
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact


//-->